Actym Therapeutics

Actym Therapeutics is a private, clinical-stage biotech developing the STACT™ platform, a systemically administered, engineered bacterial delivery system designed to localize in tumors and produce immunotherapies on-site to avoid systemic toxicity. The company's lead candidate, ACTM-838, is in Phase 1 trials for solid tumors, targeting a major unmet need in immuno-oncology. Backed by notable venture capital investors and led by a team with deep expertise, Actym aims to overcome tumor resistance by harnessing the innate intelligence of bacteria to create potent and localized immune responses.

STACT™ (S. Typhimurium Anti-Cancer Therapy) platform: a systemically administered, genetically attenuated Salmonella Typhimurium bacterial vector engineered to selectively localize and proliferate in tumors and locally produce multiple therapeutic payloads to avoid systemic toxicity.

Actym competes in the crowded immuno-oncology space against other novel modalities like oncolytic viruses (e.g., Amgen's Imlygic), intratumoral injectables, and other microbial therapies (e.g., from BioNTech, Genentech). Its key differentiation is the systemic administration and tumor-localized production of payloads by engineered bacteria, a approach with fewer direct competitors but significant technical and clinical hurdles to overcome.